الفهرس 
? Contrast-Induced NephropathyOnly 14 pages are availabe for public view
 |  | from | 176 |  |  |
| | | from | 176 | | |
Abstract
Contrast induced nephropathy (CIN) is defined as is most commonly defined as a 25% increase in serum creatinine from basal level or an absolute increase of at least 0.5 mg/dL that occurs within 48 hours after contrast administration and persisting for two to five days.
The most reliable method for the prevention of CIN is through adequate pre-procedural hydration. Other proposed methods include the use of statins, acetylcysteine, sodium bicarbonate infusion and ascorbic acid.
Trimetazidine is a metabolic anti-ischemic drug which is proposed to be beneficial in reducing the incidence of CIN.
Allopurinol works as an antioxidant drug which is thought to have a beneficial role in reducing the incidence of CIN.
The aim of the work is to evaluate the role of trimetazidine and allopurinol in reducing the incidence of CIN following contrast media injection.
This study was conducted on 120 patients presented to Ain Shams university hospitals and opting for coronary angiography procedures within the period between February 2017 and August 2017.
The patients were divided into 3 equal groups each including 40 patients where all groups received parenteral hydration in the form of isotonic saline at a rate of 1 mg/kg body weight per hour starting 12 hours before angiography and up to 12 hours thereafter. In group 1, patients received only saline hydration therapy, group 2 patients received additional medication in the form of trimetazidine 35 mg twice daily for 72 hours and starting 48 hours before the procedure and group 3 patients received allopurinol 300mg once daily orally for 72 hours and starting 48 hours before the procedure.
The 3 groups where matched as regards serum creatinine and creatinine clearance (CrCl) before the procedure. However, creatinine clearance before the procedure was higher in the allopurinol group when compared to control group with statistical significance, p=0.029.